{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=ribociclib&page=2", "query": { "intervention": "ribociclib", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=ribociclib&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-06-07T11:57:55.645Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03090165", "title": "Ribociclib and Bicalutamide in AR+ TNBC", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Triple Negative Breast Cancer" ], "interventions": [ { "name": "ribociclib", "type": "DRUG" }, { "name": "Bicalutamide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Kari Wisinski", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 37, "start_date": "2018-05-07", "completion_date": "2026-10", "has_results": false, "last_update_posted_date": "2026-01-02", "last_synced_at": "2026-06-07T11:57:55.645Z", "location_count": 6, "location_summary": "Chicago, Illinois • Lansing, Michigan • New Brunswick, New Jersey + 3 more", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Lansing", "state": "Michigan" }, { "city": "New Brunswick", "state": "New Jersey" }, { "city": "Rochester", "state": "New York" }, { "city": "Hershey", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT03090165" }, { "nct_id": "NCT07086196", "title": "A Study of Real-World Outcomes of Ribociclib in First-Line Treatment for Metastatic HR+/HER2- Breast Cancer", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Metastatic HR+/HER2- Breast Cancer" ], "interventions": [], "intervention_types": [], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 350, "start_date": "2024-05-30", "completion_date": "2024-08-30", "has_results": false, "last_update_posted_date": "2025-07-25", "last_synced_at": "2026-06-07T11:57:55.645Z", "location_count": 1, "location_summary": "East Hanover, New Jersey", "locations": [ { "city": "East Hanover", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT07086196" }, { "nct_id": "NCT05996107", "title": "Study of Ribociclib Administered Concurrently With Postoperative Radiation Therapy in Patients With High-Risk, HR+/HER2- Breast Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Ribociclib", "type": "DRUG" }, { "name": "Postoperative Radiation Therapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "University of Michigan Rogel Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 30, "start_date": "2024-02-27", "completion_date": "2030-06", "has_results": false, "last_update_posted_date": "2026-01-28", "last_synced_at": "2026-06-07T11:57:55.645Z", "location_count": 3, "location_summary": "Ann Arbor, Michigan • Wyoming, Michigan • Cleveland, Ohio", "locations": [ { "city": "Ann Arbor", "state": "Michigan" }, { "city": "Wyoming", "state": "Michigan" }, { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT05996107" }, { "nct_id": "NCT03070301", "title": "A Study of LEE011 With Everolimus in Patients With Advanced Neuroendocrine Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Neuroendocrine Tumors" ], "interventions": [ { "name": "LEE011", "type": "DRUG" }, { "name": "everolimus", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 21, "start_date": "2017-02-27", "completion_date": "2024-01-31", "has_results": true, "last_update_posted_date": "2024-10-10", "last_synced_at": "2026-06-07T11:57:55.645Z", "location_count": 5, "location_summary": "Boston, Massachusetts • New York, New York • Houston, Texas", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03070301" }, { "nct_id": "NCT02985125", "title": "LEE011 Plus Everolimus in Patients With Metastatic Pancreatic Adenocarcinoma Refractory to Chemotherapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Metastatic Pancreatic Adenocarcinoma" ], "interventions": [ { "name": "LEE011", "type": "DRUG" }, { "name": "Everolimus", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Georgetown University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 12, "start_date": "2017-05-04", "completion_date": "2020-09-28", "has_results": true, "last_update_posted_date": "2026-04-07", "last_synced_at": "2026-06-07T11:57:55.645Z", "location_count": 1, "location_summary": "Washington D.C., District of Columbia", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT02985125" }, { "nct_id": "NCT02657928", "title": "Ribociclib and Letrozole in Treating Patients With Relapsed ER Positive Ovarian, Fallopian Tube, Primary Peritoneal, or Endometrial Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Estrogen Receptor Positive", "Postmenopausal", "Recurrent Fallopian Tube Carcinoma", "Recurrent Ovarian Carcinoma", "Recurrent Primary Peritoneal Carcinoma", "Recurrent Uterine Corpus Carcinoma" ], "interventions": [ { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Letrozole", "type": "DRUG" }, { "name": "Ribociclib", "type": "DRUG" } ], "intervention_types": [ "OTHER", "DRUG" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 40, "start_date": "2016-07-08", "completion_date": "2020-10-07", "has_results": true, "last_update_posted_date": "2021-10-26", "last_synced_at": "2026-06-07T11:57:55.645Z", "location_count": 3, "location_summary": "Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT02657928" }, { "nct_id": "NCT05161195", "title": "Roll-over Study to Allow Continued Access to Ribociclib", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Metastatic Breast Cancer" ], "interventions": [ { "name": "Ribociclib", "type": "DRUG" }, { "name": "Letrozole", "type": "DRUG" }, { "name": "Anastrozole", "type": "DRUG" }, { "name": "Goserelin", "type": "DRUG" }, { "name": "Tamoxifen", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 134, "start_date": "2022-07-07", "completion_date": "2030-08-14", "has_results": false, "last_update_posted_date": "2026-04-02", "last_synced_at": "2026-06-07T11:57:55.645Z", "location_count": 16, "location_summary": "Chandler, Arizona • Fayetteville, Arkansas • Beverly Hills, California + 13 more", "locations": [ { "city": "Chandler", "state": "Arizona" }, { "city": "Fayetteville", "state": "Arkansas" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Fort Collins", "state": "Colorado" }, { "city": "Orange", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05161195" }, { "nct_id": "NCT02632045", "title": "Study of Efficacy of Ribociclib After Progression on CDK4/6 Inhibition in Patients With HR+ HER2- Advanced Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Breast Cancer", "Breast Carcinoma" ], "interventions": [ { "name": "LEE-011", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Melissa K Accordino", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 169, "start_date": "2016-03", "completion_date": "2022-01-04", "has_results": true, "last_update_posted_date": "2024-12-06", "last_synced_at": "2026-06-07T11:57:55.645Z", "location_count": 13, "location_summary": "Birmingham, Alabama • Atlanta, Georgia • Chicago, Illinois + 7 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Westwood", "state": "Kansas" }, { "city": "Lake Success", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02632045" }, { "nct_id": "NCT06625775", "title": "Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumor, Adult", "Metastatic Breast Cancer", "Advanced Breast Cancer", "HER2 Mutation-Related Tumors", "HER2-positive Metastatic Breast Cancer", "KRAS Mutant Metastatic Colorectal Cancer", "Metastatic Lung Cancer", "Metastatic Colorectal Cancer", "Advanced Lung Cancer", "HR-positive, HER2-negative Advanced Breast Cancer", "HER2-positive Advanced Breast Cancer" ], "interventions": [ { "name": "BBO-10203", "type": "DRUG" }, { "name": "Trastuzumab", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" }, { "name": "Ribociclib", "type": "DRUG" }, { "name": "FOLFOX", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 392, "start_date": "2024-10-29", "completion_date": "2028-11", "has_results": false, "last_update_posted_date": "2026-04-13", "last_synced_at": "2026-06-07T11:57:55.645Z", "location_count": 19, "location_summary": "Duarte, California • Los Angeles, California • San Diego, California + 13 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06625775" }, { "nct_id": "NCT05843253", "title": "Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "High Grade Glioma", "Diffuse Intrinsic Pontine Glioma", "Anaplastic Astrocytoma", "Glioblastoma", "Glioblastoma Multiforme", "Diffuse Midline Glioma, H3 K27M-Mutant", "Metastatic Brain Tumor", "WHO Grade III Glioma", "WHO Grade IV Glioma", "Diffuse Hemispheric Glioma, H3 G34-Mutant" ], "interventions": [ { "name": "Ribociclib", "type": "DRUG" }, { "name": "Everolimus", "type": "DRUG" }, { "name": "Temozolomide (TMZ)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Nationwide Children's Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Months", "maximum_age": "39 Years", "sex": "ALL", "summary": "12 Months to 39 Years" }, "enrollment_count": 120, "start_date": "2024-08-22", "completion_date": "2034-08-28", "has_results": false, "last_update_posted_date": "2026-05-29", "last_synced_at": "2026-06-07T11:57:55.645Z", "location_count": 11, "location_summary": "Aurora, Colorado • Washington D.C., District of Columbia • Chicago, Illinois + 8 more", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT05843253" } ] }